Generated by OpenAI’s DALL·E / ETX Majelan
(ETX Daily Up) – OpenAI, the publisher of ChatGPT, has teamed up with a start-up specializing in life extension to develop an artificial intelligence model dedicated to the study of stem cells. Their stated objective is to gain up to ten years of additional life for the human species.
OpenAI has developed a new artificial intelligence model in collaboration with Retro Biosciences. It aims to extend life expectancy by studying Yamanaka factors, a set of proteins capable of reprogramming adult cells into pluripotent stem cells. This exclusive model, GPT-4b micro, was designed to pave the way for the regeneration of different cell types but also for the creation of tailor-made organs in the best case scenario.
This model has been specially trained to propose optimal modifications of Yamanaka factors, these combinations of proteins essential for the reprogramming of cells into stem cells. The idea is that GPT-4b micro could make the cellular reprogramming process much faster and more reliable than currently. All this research could, one day, open up new perspectives in the field of health and aging, and therefore help to prolong everyone’s life.
-At the moment, GPT-4b micro is only used by Retro Biosciences and OpenAI, on an experimental basis. No information has yet filtered regarding an upcoming public availability of the model. Basically, the common denominator between OpenAI and Retro Biosciences is Sam Altman, co-founder and CEO of the first entity and investor in the second.
Tech
